Previous 10 | Next 10 |
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the 19th Annual Ne...
Key Changes to 2020 Plan : - Launch of RHA® fillers, and associated hiring of 100 field representatives, pushed back one quarter due to COVID-19 situation and temporary closure of Teoxane’s Swiss manufacturing facility - - JUNIPER Phase 2 trial for adult upper limb spas...
AbbVie (NYSE: ABBV ) downgraded to Hold at Societe Generale. More news on: AbbVie Inc., Tandem Diabetes Care, Inc., Universal Health Services, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Revance Therapeutics, Inc. (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Revance reported earnings yesterday. 4Q19 EPS of $(0.99) was slightly below FactSet consensus of $(0.95) which we believe it is immaterial...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Cowen 40th Ann...
Image source: The Motley Fool. Revance Therapeutics (NASDAQ: RVNC) Q4 2019 Earnings Call Feb 24, 2020 , 4:30 p.m. ET Operator Continue reading
Revance Therapeutics, Inc. (RVNC) Q4 2019 Results Earnings Conference Call February 24, 2020, 4:30 am ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Mark Foley - President, Chief Executive Officer Dustin Sjuts - Chief C...
Revance Therapeutics (NASDAQ: RVNC ): Q4 GAAP EPS of -$0.99 misses by $0.05 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today repo...
Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection ...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...